Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info: https://youtu.be/811v7RLXP9M
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country
MEBO TMAU TESTING DISCONTINUED
(2012-2017)

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO survey for Dr Hazen click here
Read more/less

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

MEBO Research Clinical Trials

Tuesday, June 26, 2012

Dr. Elizabeth Shephard's presentation: FMO3 - a protein that can multi-task

halitosis researchWe are currently working on providing you with Dr. Elizabeth Shephard's powerpoint presentation that she created specifically for the MEBO Conference part of our Miami Beach Meetup 2012. Meanwhile, until we are able to post this in this blog, I would like to offer you a link to it, and a link for you to download FREE QuickTime 7. Please note that QuickTime7 is free, and if you are asked to pay, then you are not in the right place. A web-embedded version of this presentation will be available in several days for me to be able to post it in this blog. Once you have downloaded QuickTime 7, you can run Dr. Shephard's powerpoint presentation using the following link:



This most valuable presentation of data highlights the dangers of certain drugs, including pesticide and psychiatric drugs, for example, for persons who have deficient metabolic clearance. Among those would be persons with FMO3 compromised systems.

Please note, that Dr. Shephard is excited with the new field of genetics called "Pharmacogenetics" which deals with how our genes influence the way we handle a drug. Pharmacogenetics is "Personalized Medicine..." and the focus treatment is "if we understand a person's genetics, can we tailor their drug treatment to get them the best response to their particular drugs."

Dr. Shephard gives us a "very short list" as examples of some FMO3 drug substrates more commonly used, including anaesthetics, a variety of anti-inflammatory (throat lozenges and sprays), anti-psychotic, and neuronal stimulant, such as nicotine. She refers to a study that has proven the inability or compromised ability of people with TMAU to be metabolize Benzydamine.

In addition, she explains how "Many drugs are metabolized by more than one enzyme" including CYPs (P450s).

I highly recommend that all persons, without exception, that suffer from any type of body odor or halitosis condition, study her presentation. All sufferers need to observe and be aware of any adverse reaction to any medication consumed, and to immediately inform their physician.

Dr. Shephard also tells us,

One thing to remember is that many people have unpleasant effects from antipsychotics and antidepressants and this may not be due to changes in FMO3.


This presentation will be put up in this blog as soon as possible.


María

María de la Torre
Founder and Executive Director

A Public Charity
www.meboresearch.org
www.brasil.meboresearch.org
maria.delatorre@meboresearch.org
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)



SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.


Please use your credit card to make your donation to MEBO.


Subscribe for latest posts : Enter your email address:

Delivered by FeedBurner


A EURORDIS and NORD Member Organization

0 comments:

Post a Comment